Candel Therapeutics announced positive immunological biomarker data from its Phase 2 PrTK05 trial for intermediate-risk localized prostate cancer, showing T-cell activation and supporting long-term clinical outcomes. This data, combined with previous findings, strengthens the mechanistic support for their therapy and keeps their Biologics License Application (BLA) submission on track for Q4 2026, indicating significant progress towards potential market approval.
Candel Therapeutics (CADL) has released encouraging immunological biomarker data from its ongoing Phase 2 PrTK05 trial for prostate cancer. The data demonstrates T-cell activation, providing mechanistic support for the long-term clinical benefits observed in previous trials, such as improved disease-free survival. This is a significant positive development for the company as it reinforces the efficacy and mechanism of action of their lead candidate, aglatimagene. The confirmation that biodistribution and shedding data are on track for the Q4 2026 BLA submission to the FDA is also crucial, signaling continued progress towards potential market approval. This news could lead to increased investor confidence and a positive short-term price movement for CADL, with long-term implications tied to the successful BLA submission and eventual commercialization.